100 related articles for article (PubMed ID: 8442150)
21. Cyclosporine monotherapy versus conventional therapy in the living-related renal transplant: a one center retrospective study.
Masri MA; Shakuntala V; Dhawan IK; Zahir M; Shanwaz M; Hayes K; Pingle A
Transplant Proc; 1993 Jun; 25(3):2248-9. PubMed ID: 8516889
[No Abstract] [Full Text] [Related]
22. Posttransplant serum creatinine area under the curve predicts renal allograft outcome.
Sumrani N; Hong J; Miles A; Markell M; Distant D; Fleishhacker J; Maursky V; Jean-Baptiste F; Sommer B
Transplant Proc; 1996 Feb; 28(1):356-7. PubMed ID: 8644260
[No Abstract] [Full Text] [Related]
23. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
Boratyńska M; Banasik M; Patrzalek D; Szyber P; Klinger M
Transplant Proc; 2005 Mar; 37(2):839-42. PubMed ID: 15848550
[TBL] [Abstract][Full Text] [Related]
24. Does acute tubular necrosis affect renal transplant outcome? The impact of rejection episodes.
Troppmann C; Almond PS; Payne WD; Dunn DL; Gores PF; Gruessner RW; Sutherland DE; Matas AJ; Najarian JS
Transplant Proc; 1993 Feb; 25(1 Pt 2):905. PubMed ID: 8442263
[No Abstract] [Full Text] [Related]
25. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
26. [Renal graft survival in patients with systemic lupus erythematosus].
Chew-Wong A; Soltero L; Diná E; Alvarez-Sandoval E; Alberú J; Gamba G; Correa-Rotter R
Rev Invest Clin; 2002; 54(1):21-8. PubMed ID: 11995403
[TBL] [Abstract][Full Text] [Related]
27. [Acute rejection in cadaveric renal transplantation under cyclosporine based therapy. Analysis of the risk factors and its influence on chronic dysfunction].
Mota A
Acta Med Port; 2004; 17(1):8-14. PubMed ID: 15636737
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for malignancy in Japanese renal transplant recipients.
Imao T; Ichimaru N; Takahara S; Kokado Y; Okumi M; Imamura R; Namba Y; Isaka Y; Nonomura N; Okuyama A
Cancer; 2007 May; 109(10):2109-15. PubMed ID: 17407138
[TBL] [Abstract][Full Text] [Related]
29. [Cancer after kidney transplantation].
Sandrini S; Setti G; Bossini N; Maiorca P
G Ital Nefrol; 2004; 21 Suppl 26():S67-73. PubMed ID: 15732048
[TBL] [Abstract][Full Text] [Related]
30. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation.
Saigal S; Norris S; Muiesan P; Rela M; Heaton N; O'Grady J
Liver Transpl; 2002 May; 8(5):482-7. PubMed ID: 12004349
[TBL] [Abstract][Full Text] [Related]
31. Early de novo malignancies after kidney transplantation.
Veroux M; Puliatti C; Fiamingo P; Cappello D; Macarone M; Puliatti D; Vizcarra D; Gagliano M; Veroux P
Transplant Proc; 2004 Apr; 36(3):718-20. PubMed ID: 15110643
[TBL] [Abstract][Full Text] [Related]
32. Malignancies in renal transplant patients: 15 years experience in Thailand.
Ativitavas T; Jirasiritham S; Ngorsakun P; Pipatpannawong K; Mavichak V
Transplant Proc; 2008 Sep; 40(7):2403-4. PubMed ID: 18790248
[TBL] [Abstract][Full Text] [Related]
33. Delayed graft function adversely affects one-year graft survival of cadaveric renal transplants.
Carmellini M; Stefano RD; Filipponi F; Rindi P; Rizzo G; Mosca F
Transplant Proc; 1996 Feb; 28(1):359-60. PubMed ID: 8644262
[No Abstract] [Full Text] [Related]
34. Graft outcome in cadaver renal transplants treated with full-dose cyclosporine induction without antibody, irrespective of graft function.
Douzdjian V; Bhaskar S; Baliga PK; Rajagopalan PR
Clin Transplant; 1997 Aug; 11(4):294-8. PubMed ID: 9267718
[TBL] [Abstract][Full Text] [Related]
35. Renal allograft function and results with cyclosporine immunosuppression in recipients of single kidneys from cadaveric donors aged 12 to 24 months.
Banowsky LH; Wright FH; Kothmann R; Floyd M; Vick S
Transplant Proc; 1996 Aug; 28(4):2121-4. PubMed ID: 8769175
[No Abstract] [Full Text] [Related]
36. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia.
Fernández A; Marcén R; Pascual J; Galeano C; Ocaña J; Arellano EM; Alfaro C; Villafruela JJ; Burgos FJ; Ortuño J
Transplant Proc; 2006 Oct; 38(8):2453-5. PubMed ID: 17097965
[TBL] [Abstract][Full Text] [Related]
37. Development of de novo malignancies following renal transplantation: a single-center study.
Suzuki S; Tanaka K; Ohsaka Y; Nakai I; Yasumura T; Ohmori Y; Oka T
Transplant Proc; 1994 Apr; 26(2):938-40. PubMed ID: 8171710
[No Abstract] [Full Text] [Related]
38. Surgical Grand Rounds from the University of Mississippi Medical Center. Renal transplantation.
South Med J; 1971 Jul; 64(7):855-9. PubMed ID: 4933015
[No Abstract] [Full Text] [Related]
39. Recurrence of cancer after renal transplantation.
Chapman JR; Sheil AG; Disney AP
Transplant Proc; 2001; 33(1-2):1830-1. PubMed ID: 11267531
[No Abstract] [Full Text] [Related]
40. Function of a transplanted kidney.
Orlowski T; Nielubowicz J; Gradowska L; Rowiński W; Klopotowska E
Pol Med J; 1967; 6(2):366-74. PubMed ID: 5339981
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
